【摘要】 心力衰竭是一种复杂的临床症状群,是各种心脏病的严重阶段。根据中国心血管病报告2015年的数据,全国心血管病患者约2.9亿,其中心力衰竭患者450万。2014年中国心力衰竭指南将ACEI/ARB类和β-受体阻滞剂类、醛固酮受体拮抗剂三药联合作为射血分数减低心力衰竭患者"金三角"治疗方案,但是5年病死率仍在50%以上。诺欣妥是一种新型的血管紧张素受体及脑啡肽酶抑制剂,通过阻断NEP抑制剂对血管紧张素的激活效应,单独发挥其舒张血管,进而降低血压及抑制RAAS的效果,可能成为ACEI/ARB的替代选择。本文就慢性心力衰竭的神经内分泌调节治疗及诺欣妥作用机制、目前临床研究和应用进行综述。更多还原

【Abstract】 Objective Heart failure(HF) is a complex clinical syndrome and a serious stage of various heart diseases. Based on the data of Cardiovascular Disease Report in China 2015, there were about 0.29 billion patients suffered from cardiovascular disease in China, included 4.5 million HF patients. ACEI/ARB plus the β-receptor blockers and aldosterone receptor antagonists recommended as "The Golden Triangle Treatment" to the patients suffered from CHF-rEF in the China Heart Failure Guidelines 2014,but the fatality rate in 5 years is still above 50%. Entresto is a new type of angiotensin receptor and brain-endorphin inhibitor by blocking the activation effect of NEP inhibitors on angiotensin, to relax blood vessel, lower blood pressure and inhibit RAAS, that may be an alternative to ACEI/ARB. In this pa per, neuroendocrine modulation therapy and the mechanism, clinical research and application about Entresto on chronic heart failure are reviewed.更多还原